Trade

with

Vermillion Inc
(NASDAQ: VRML)
AdChoices
1.60
+0.02
+1.20%
After Hours :
-
-
-

Open

1.60

Previous Close

1.58

Volume (Avg)

3.61k (30.62k)

Day's Range

1.55-1.60

52Wk Range

1.42-3.83

Market Cap.

56.72M

Dividend Rate ( Yield )

-

Beta

1.86

Shares Outstanding

35.90M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Diagnostics & Research
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 2.57M

    • Net Income

    • -8.82M

    • Market Cap.

    • 56.72M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -537.46

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.86

    • Forward P/E

    • -

    • Price/Sales

    • 18.73

    • Price/Book Value

    • 3.20

    • Price/Cash flow

    • -3.85

      • EBITDA

      • -8.75M

      • Return on Capital %

      • -67.68

      • Return on Equity %

      • -90.43

      • Return on Assets %

      • -67.68

      • Book Value/Share

      • 0.49

      • Shares Outstanding

      • 35.90M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 2.50

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.30

          • 21.91

          • Net Income

            YTD/YTD (last year)

          • -

          • -5.55

          • Net Income

            Q/Q (last year)

          • -

          • 0.44

          • Sales (Revenue)

            5-Year Annual Average

          • 83.30

          • 47.82

          • Net Income

            5-Year Annual Average

          • -

          • 4.98

          • Dividends

            5-Year Annual Average

          • -

          • 5.31

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 90.49

            • 42.70

            • Pre-Tax Margin

            • -537.46

            • 11.63

            • Net Profit Margin

            • -537.46

            • 9.55

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 43.76

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 11.34

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 52.13B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.62

              • Current Ratio

              • 4.07

              • 1.23

              • Quick Ratio

              • 3.94

              • 0.76

              • Interest Coverage

              • -

              • 5.98

              • Leverage Ratio

              • 1.33

              • 2.16

              • Book Value/Share

              • 0.49

              • 14.94

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -3.26

                • 32.15

                • P/E Ratio 5-Year High

                • -74.92

                • 325.07

                • P/E Ratio 5-Year Low

                • -2.14

                • 154.73

                • Price/Sales Ratio

                • 17.54

                • 2.24

                • Price/Book Value

                • 2.99

                • 2.92

                • Price/Cash Flow Ratio

                • -3.85

                • 18.35

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -90.43

                        (-)

                      • 9.34

                        (9.80)

                      • Return on Assets %

                        (5-Year Average)

                      • -67.68

                        (-163.80)

                      • 4.63

                        (5.44)

                      • Return on Capital %

                        (5-Year Average)

                      • -84.26

                        (-)

                      • 5.73

                        (6.77)

                      • Income/Employee

                      • -

                      • 17.17k

                      • Inventory Turnover

                      • -

                      • 5.07

                      • Asset Turnover

                      • 0.13

                      • 0.48

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -8.86M
                      Operating Margin
                      -345.40
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -3.85
                      Ownership

                      Institutional Ownership

                      24.77%

                      Top 10 Institutions

                      25.02%

                      Mutual Fund Ownership

                      1.12%

                      Float

                      60.00%

                      5% / Insider Ownership

                      11.05%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Total Stock Mkt Idx

                      •  

                        202,264

                      • 0.00

                      • 0.56

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        65,547

                      • 0.00

                      • 0.18

                      • iShares Micro-Cap

                      •  

                        56,368

                      • 0.00

                      • 0.14

                      • Vanguard Extended Market Index Fund

                      •  

                        49,637

                      • 0.00

                      • 0.14

                      • Vanguard Balanced Index Fund

                      •  

                        20,667

                      • 0.00

                      • 0.06

                      • Fidelity Spartan® Total Market Idx Fund

                      •  

                        5,249

                      • 0.00

                      • 0.01

                      • AXA/Lord Abbett Micro Cap Portfolio

                      •  

                        4,879

                      • 0.00

                      • 0.01

                      • Wilshire Micro-Cap ETF

                      •  

                        3,686

                      • 0.00

                      • 0.01

                      • Fidelity® Nasdaq Composite Tr Stk Fund

                      •  

                        864

                      • 9.37

                      • 0.00

                      • Vanguard US Equity Index

                      •  

                        412

                      • 0.00

                      • 0.00

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Oracle Investment Management Inc

                      •  

                        7,139,960

                      • 0.00%

                      • 19.89

                      • Feinberg Family Trust

                      •  

                        530,000

                      • 0.00%

                      • 2.26

                      • Renaissance Technologies Corp

                      •  

                        301,500

                      • +6.84%

                      • 0.84

                      • Vanguard Group, Inc.

                      •  

                        255,752

                      • 0.00%

                      • 0.71

                      • HighTower Advisors, LLC

                      •  

                        179,000

                      • +26.06%

                      • 0.50

                      • Geode Capital Management, LLC

                      •  

                        71,586

                      • -0.05%

                      • 0.20

                      • Dominick & Dominick LLC

                      •  

                        64,300

                      • +7.53%

                      • 0.18

                      • BlackRock Fund Advisors

                      •  

                        60,465

                      • +2.94%

                      • 0.17

                      • California Public Employees Retrmnt Sys

                      •  

                        54,500

                      • 0.00%

                      • 0.15

                      • Trellus Management Company, LLC

                      •  

                        42,918

                      • 0.00%

                      • 0.12

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Diagnostics & Research

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Vermillion Inc was incorporated on California on December 9, 1993. The Company is engaged in discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes ...morefor patients with gynecologic cancers and related diseases. The Company concentrates its development of novel diagnostic tests in the fields of gynecologic oncology and womens health, with the initial focus on guiding the referral of women with ovarian cancer to a cancer specialist for surgery. Its commercial efforts include direct marketing and sales activities as well as partnerships with main companies in womens health. Its main product, OVA1, is an ovarian cancer test system that integrates a software algorithm and blood test cleared by the FDA in September 2009. OVA...more1 was launched in March 2010 by Quest Diagnostics under the terms of a strategic alliance agreement that the Company terminated in August 2013. In September 2010, it announced that OVA1 had obtained a CE mark, a requirement for marketing the OVA1 test in the European Union. OVA1 has satisfied all certification requirements to complete its declaration of conformity. OVA1 addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. In 2013, all of its product revenue was generated through Quest Diagnostics. It has two ongoing R&D-sponsored initiatives to support OVA1 market development and adoption as an improved standard of care in the pre-surgical triage and evaluation of adnexal masses. The first is a main new clinical study of OVA1, focused on its performance in the predominantly pre-menopausal non-gynecologic oncologist patient population. The second R&D initiative supporting OVA1 is a series of Vermillion-assisted, independent clinical research studies of OVA1. Through this program, Vermillion offers limited support for well-qualified principal investigators in the form of materials, testing services, and scientific consulting. As a result, the Company is currently in discussion with various potential investigators to support new research publications on OVA1s clinical utility, cost-effectiveness, and potential line extensions. As of December 31, 2013, its clinical diagnostics patent portfolio included 27 issued United States patents, 17 pending United States patent applications, and various pending patent applications and issued patents outside the United States. The Company competes with companies in the United States and abroad that are engaged in the development and commercialization of novel biomarkers. Its activities related to diagnostic products are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of its products.lessless

                      Key People

                      Mr. James T. LaFrance

                      Chairman of the Board/Director/President/CEO

                      Mr. Eric Schoen

                      CFO/Chief Accounting Officer/Vice President, Divisional

                      Ms. Holly B. Bauzon

                      Vice President, Divisional

                      Mr. James S. Burns

                      Director

                      Peter S. Roddy

                      Director

                      • Vermillion Inc

                      • 12117 Bee Caves Road, Building Three

                      • Austin, TX 78738

                      • USA.Map

                      • Phone: +1 512 519-0400

                      • Fax: +1 512 439-6980

                      • vermillion.com

                      Incorporated

                      1993

                      Employees

                      26

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: